In September 2024, a significant study published in the journal Cancers revealed a troubling link between the prolonged use of Depo-Provera, an injectable contraceptive containing depot medroxyprogesterone acetate (dMPA), and an increased risk of developing cerebral meningiomas. The large-scale case-control study analyzed over 117,000 meningioma cases and more than one million matched controls using data spanning 2006–2022. It found that “injection exposure” to medroxyprogesterone acetate (Depo-Provera) was associated with a 53% increase in the risk of developing meningiomas, with the risk becoming stronger with prolonged use.
Previous Evidence Supports the Findings
The September study builds on earlier evidence from a study published in March 2024 in The BMJ. Titled “Use of Progestogens and the Risk of Intracranial Meningioma: National Case-Control Study,” this research also identified a concerning link between the use of progestogens, including injectable medroxyprogesterone acetate (Depo-Provera), and an increased risk of intracranial meningiomas. Together, these studies underscore growing concerns about the safety of prolonged exposure to injectable progestogens, particularly for women relying on Depo-Provera for long-term contraceptive needs.
Key Findings from the September Study
- Association Specific to Cerebral Meningiomas:
- The study highlighted that the increased risk was specific to cerebral meningiomas, with no significant association observed for spinal meningiomas.
- Prolonged use of injectable MPA was linked to a steep rise in risk, peaking at over threefold odds for those with exposure exceeding three years.
- Dose-Response Relationship:
- A clear correlation was observed between the duration of Depo-Provera use and increased odds of developing cerebral meningiomas.
- Risks were highest among women who had used the injectable form for extended periods, underscoring existing medical guidelines advising against prolonged use unless alternative options are unsuitable.
- Progesterone Receptor Link:
- Meningiomas often express progesterone receptors, suggesting a biological pathway for tumor growth in response to synthetic progesterone like MPA.
Implications for Depo-Provera Users
The findings from these studies emphasize the need for caution when using Depo-Provera for extended durations. While meningiomas are often benign, their growth can impact quality of life and, in some cases, require surgical intervention. Patients and healthcare providers must carefully weigh the risks of prolonged Depo-Provera use against its contraceptive benefits.
Find Out if You Qualify For the Depo-Provera Lawsuit
Speak With Our Nationally Recognized Women's Health Litigation Team
215-608-9645Anapol Weiss Advocates for Accountability
At Anapol Weiss, we are dedicated to holding pharmaceutical companies accountable for the safety of their products. Our firm has filed several of the first lawsuits against Pfizer, alleging that the company failed to adequately warn women about the increased risk of cerebral meningiomas linked to prolonged Depo-Provera use. The findings from the Cancers study and the March 2024 BMJ study provide critical support for these claims, highlighting the urgent need for better transparency and patient protection.
If you or a loved one developed a meningioma after using Depo-Provera, our experienced legal team is here to help. Contact us for a consultation to explore your legal rights and options.
